ITM Isotope Technologies Munich SE announced the presentation of the design of its new phase III trial, COMPOSE, with the radiopharmaceutical candidate n.c.a. ¹⁷⁷Lu-edotreotide in patients with well-differentiated aggressive grade 2 and grade 3 somatostatin receptor-positive gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) at the North American Neuroendocrine Society (NANETS) annual symposium 2021, held virtually from November 3 – 6, 2021. COMPOSE is ITM’s second phase III trial with its lead candidate n.c.a. ¹⁷⁷Lu-edotreotide, a Targeted Radionuclide Therapy consisting of the high-quality radioisotope no-carrier-added lutetium-177 fused with an innovative somatostatin analogue to specifically target GEP-NETs. N.c.a. ¹⁷⁷Lu-edotreotide is also currently being investigated in an ongoing phase III study, COMPETE, in patients with grade 1 and 2 GEP-NETs.

To read more please visit:

ITM Introduces Second Phase III Trial, COMPOSE, with n.c.a. Lutetium-177-Edotreotide for Neuroendocrine Tumors at NANETS Annual Symposium 2021

Source: ITM